Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide

AUTOR(ES)

Wu, Chang-Jer

FONTE

American Society for Microbiology

RESUMO

Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 μM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.

Documentos Relacionados

• Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus
• Severe Acute Respiratory Syndrome Coronavirus Phylogeny: toward Consensus
• Mosaic Evolution of the Severe Acute Respiratory Syndrome Coronavirus
• Inhibition of Severe Acute Respiratory Syndrome Virus Replication by Small Interfering RNAs in Mammalian Cells
• Small molecules targeting severe acute respiratory syndrome human coronavirus